ホーム > 市場調査レポート > 医薬品 > 創薬 > 創薬分野の動向と新技術
カテゴリ
医薬品 (4962)
OTC (153)
がん (943)
ドラッグデリバリー (185)
ワクチン (181)
感染症 (353)
規制環境 (132)
後発医薬品 (135)
骨疾患 (37)
処方薬 (158)
神経疾患 (174)
精神疾患 (89)
製薬企業関連 (531)
創薬 (1523)
糖尿病 (192)
動物用医薬 (17)
肥満症 (44)
市場調査レポート

創薬分野の動向と新技術

Trends and Emerging Technologies in Drug Discovery

発行 Frost & Sullivan
出版日 2005年12月 商品コード 36014
ページ情報 英文 61 pages
価格
こちらの商品の販売は終了いたしました。

当商品の販売は、2011年07月19日を持ちまして終了しました。

原文目次

Abstract

Research Overview

This Research Service analyzes the emerging trends and technologies in the United States drug discovery industry. It provides a 30,000 foot view of the trends and near term forecasts in these areas while exploring the role these technologies may play in the future.

Table Of Contents

1. OVERVIEW OF TRENDS AND EMERGING TECHNOLOGIES IN DRUG DISCOVERY

Introduction

  • 1. Overview
  • 2. Scope and Segmentation
  • 3. Definitions and Acronyms

2. CELL-BASED SCREENING MARKET

Market Overview

  • 1. Introduction
  • 2. Segment Overview
  • 3. Market Challenges

4. Strategic Recommendations

Forecasts and Trends

  • 1. Market Drivers
  • 2. Market Restraints
  • 3. Competitive Segmentation
  • 4. Competitive Analysis
  • 5. Revenue Forecast

3. PROTEOMICS MASS SPECTROMETRY SOFTWARE MARKET

Market Overview

  • 1. Introduction
  • 2. Segment Overview
  • 3. Market Challenges
  • 4. Strategic Recommendations

Forecasts and Trends

  • 1. Market Drivers
  • 2. Market Restraints
  • 3. Competitive Segmentation
  • 4. Competitive Analysis
  • 5. Revenue Forecast

4. DNA MICROARRAY CLINICAL APPLICATION MARKET

Market Overview

  • 1. Introduction
  • 2. Segment Overview
  • 3. Market Challenges
  • 4. Strategic Recommendations

Forecasts and Trends

  • 1. Market Drivers
  • 2. Market Restraints
  • 3. Competitive Segmentation
  • 4. Competitive Analysis
  • 5. Revenue Forecast

5. DECISION SUPPORT DATABASE

Decision Support Database

  • 1. Number of Biotechnology Companies
  • 2. Private Investment in Biotechnology
  • 3. Government R&D Biotechnology Investment
  • 4. Percent of Investment into Biotechnology by Government
Back to Top